New Therapeutic Developments for Relapsed/Refractory Multiple Myeloma

In this online program, experts discuss how to best use new therapeutic agents for patients with relapsed/refractory multiple myeloma. Watch the on-demand Webcast and download the slides from a dynamic online live CCO symposium, plus access expert commentaries and a podcast on the new data to learn more about how to select optimal regimens for your patients with advanced myeloma.
person default
Paula Rodriguez-Otero, MD, PhD
Jesús F. San-Miguel, MD, PhD
person default
Prof. Dr. med. Katja Weisel

Podcast

In this podcast episode, listen to myeloma experts Jesús F. San-Miguel, MD, PhD; Paula Rodriguez-Otero, MD, PhD; and Prof. Dr. med. Katja Weisel answer audience questions from a live CCO Webinar on available and emerging therapeutic strategies for patients with early and late relapsed/refractory multiple myeloma.

Released: September 3, 2020

On-Demand Webcast

Watch this on-demand Webcast capturing a live CCO Webinar featuring expert presentations on new agents and approaches for relapsed/refractory multiple myeloma, including strategies for early relapse, BCMA-targeted treatments for late relapse, and novel targeted agents.

Downloadable Slidesets

Download these slides to review expert insights on available treatments for patients with early relapsed, refractory MM

Jesús F. San-Miguel, MD, PhD Released: July 15, 2020

Download these slides to review expert insights on available treatments for patients with late relapsed, refractory MM.

person default Paula Rodriguez-Otero, MD, PhD Released: July 16, 2020

Download these slides to review expert insights on novel agents with new targets for patients with relapsed, refractory MM.

person default Prof. Dr. med. Katja Weisel Released: July 20, 2020

ClinicalThought

How will you incorporate belantamab mafodotin into your clinical practice for patients with relapsed/refractory multiple myeloma? Here are my thoughts.

person default Paula Rodriguez-Otero, MD, PhD Released: August 25, 2020

Read my thoughts on treating patients with multiple myeloma who experience biochemical relapse.

Jesús F. San-Miguel, MD, PhD Released: September 22, 2020
Provided by Clinical Care Options, LLC, in partnership with Clinical Care Options Global B.V.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
GlaxoSmithKline

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue